头孢洛林或万古霉素联合碳青霉烯类增强对耐甲氧西林金黄色葡萄球菌的杀伤作用
本研究通过棋盘法、时间杀菌试验、人全血杀菌试验及小鼠菌血症模型,评估碳青霉烯类(厄他培南或美罗培南)联合头孢洛林或万古霉素对比单药治疗耐甲氧西林金黄色葡萄球菌(MRSA)的效果;并利用转录组分析、血小板及抗菌肽LL-37杀伤试验探讨机制。结果显示联合方案在体外和体内均呈现显著协同作用,亚治疗浓度头孢洛林-碳青霉烯类预处理可降低MRSA耐药性、毒力及免疫逃逸相关转录水平,并减少血小板损伤、增强血小板和LL-37的杀伤。作者认为碳青霉烯类辅助治疗的成功由多种机制驱动,各机制均需进一步研究。
要点
- 碳青霉烯类与头孢洛林或万古霉素联合对MRSA在体外和体内均显示显著协同作用。
- 亚治疗浓度头孢洛林-碳青霉烯类预处理使MRSA转录组向耐药性、毒力及宿主免疫逃逸降低的方向改变。
- 上述预处理的MRSA上清液较单药治疗组引起更轻的血小板损伤,且MRSA对人血小板和LL-37杀伤的易感性增加。
核心结论
- 碳青霉烯类辅助治疗的成功似乎由多种机制驱动,包括与一线抗MRSA药物的直接药物协同、耐药和毒力因子的减弱以及免疫介导杀伤的增强,每种机制均需进一步研究。
研究设计与样本
- 采用棋盘法、时间杀菌试验、人全血杀菌试验及小鼠菌血症模型评估联合治疗与单药治疗对MRSA的效果。
- 对经亚治疗浓度头孢洛林和碳青霉烯类预处理的MRSA进行转录组分析,并行人类血小板及抗菌肽杀伤试验。
- 用上述MRSA分离株的上清液处理血小板,通过乳酸脱氢酶释放试验评估细胞毒性。
主要发现
- 尽管碳青霉烯类不用于MRSA,体外和体内均发现其与头孢洛林或万古霉素之间存在显著协同作用。
- 经亚治疗浓度头孢洛林-碳青霉烯类预处理的MRSA显示转录组改变,提示抗生素耐药性、毒力和宿主免疫逃逸降低。
- 这些MRSA分离株的上清液较单药治疗引起更轻的血小板损伤。
- 经头孢洛林和碳青霉烯类预处理的MRSA对人血小板和抗菌肽LL-37杀伤的易感性增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure, even when antibiotics showing in vitro susceptibility are used. Early optimization of therapy is crucial to reduce morbidity and mortality. Building on our previous research on carbapenem therapy for methicillin-susceptible S aureus bacteremia, we examined the utility of adjunctive carbapenems (ertapenem or meropenem) to enhance the efficacy of ceftaroline or vancomycin for treatment of MRSA. METHODS: The effectiveness of combination therapy versus monotherapy against MRSA was assessed using checkerboard, time-kill, and human whole blood killing assays, as well as a murine bacteremia model. Additionally, we performed transcriptomic analysis and conducted human platelet and antimicrobial peptide killing assays on MRSA pretreated with subtherapeutic concentrations of ceftaroline and carbapenems. The supernatants from these MRSA isolates were used to treat platelets, and cytotoxicity was assessed via lactate dehydrogenase release assays. RESULTS: Although not used for MRSA, we identified striking in vitro and in vivo synergy between carbapenems and ceftaroline or vancomycin. MRSA pretreated with subtherapeutic ceftaroline-carbapenem therapy revealed transcriptional shifts indicative of reduced antibiotic resistance, virulence, and host immune evasion. Supernatants from these MRSA isolates also caused less platelet injury compared to monotherapy. Furthermore, MRSA pretreated with ceftaroline and carbapenems demonstrated increased susceptibility to killing by human platelets and the antimicrobial peptide LL-37. CONCLUSIONS: The therapeutic success of adjunctive carbapenems appears driven by multiple mechanisms, including direct drug-drug synergy with first-line anti-MRSA agents, attenuation of resistance and virulence factors, and enhancement of immune-mediated killing, each warranting further investigation.
引用
- Jankeel A, Pérez-Parra G, Khetarpal AK, et al. Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems. J Infect Dis. 2025. PMID: 39777519. doi:10.1093/infdis/jiaf010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。